Literature DB >> 28132363

Migraine during perimenopause.

Giovanni Battista Allais1, Giulia Chiarle2, Fabiola Bergandi2, Chiara Benedetto2.   

Abstract

Entities:  

Year:  2015        PMID: 28132363      PMCID: PMC4759136          DOI: 10.1186/1129-2377-16-S1-A25

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   7.277


× No keyword cloud information.
Migraine affects the female sex to a greater extent than the male, with a female:male ratio of 3:1. Hormonal fluctuations during the reproductive life may influence migraine occurrence and intensity, both in a positive or negative way. Many women experience migraine approaching menopause, but the trend of migraine symptoms may vary according to the different stages of the perimenopause. If a woman is already a migraineur subject, the attacks often worsen during both the early and late phases of menopausal transition, whereas an onset of migraine is quite rare[1]. According to some authors, women with premenstrual syndrome (PMS) before menopause have an increased prevalence of migraine in late menopausal transition, and a subsequent reduction of the attacks in postmenopause[2]. The presence of PMS can be considered one of the predictors of migraine trend during the menopausal transition, since women with PMS are more sensitive to hormonal fluctuations and more prone to develop moderate to severe menopausal symptoms[3]. Hormone replacement therapy (HRT) can be used during the late premenopausal phase and the first years of postmenopause in order to counteract climacteric symptoms[4]. The effect of HRT on migraine has been investigated, either in its role of provoking or preventing the attacks. HRT should be administered continuously, without intervals, to avoid sudden estrogen deprivation and the consequent possible onset of migraine[5]. Treatment with estradiol-based gels and transdermal patches is preferable to oral formulation as it maintains constant serum hormone levels. In contrast to guidelines on the use of estroprogestinic contraceptives, migraine with aura is not an absolute contraindication to HRT when the way of administration is topical with a low dose of natural estrogens. If the aura recurs or worsens, HRT should be in any case discontinued[6]. When the effect of tibolone versus continuous combined HRT regimen in migraine is compared, a significant reduction in the hours with pain-limiting daily activities and of the amount of analgesics intake can be observed, even if there is no reduction of the days with migraine[7]. Natural menopause is associated with a lower incidence of migraine as compared with surgical menopause[8]; data on migraine prevalence in relation to the type of surgical procedure are till now unclear and contradictory[9].

Conflict of interest

None to declare.
  9 in total

1.  Effects of oral and transdermal estrogen replacement on migraine.

Authors:  A MacGregor
Journal:  Cephalalgia       Date:  1999-03       Impact factor: 6.292

2.  Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches.

Authors:  Rossella E Nappi; Grazia Sances; Arianna Sommacal; Silvia Detaddei; Fabio Facchinetti; Silvano Cristina; Franco Polatti; Giuseppe Nappi
Journal:  Menopause       Date:  2006 Sep-Oct       Impact factor: 2.953

3.  Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study.

Authors:  E A MacGregor; A Frith; J Ellis; L Aspinall; A Hackshaw
Journal:  Neurology       Date:  2006-12-26       Impact factor: 9.910

Review 4.  Perimenopausal migraine in women with vasomotor symptoms.

Authors:  E Anne MacGregor
Journal:  Maturitas       Date:  2011-11-23       Impact factor: 4.342

5.  Hysterectomized women with ovarian conservation report more severe climacteric complaints than do normal climacteric women of similar age.

Authors:  A Oldenhave; L J Jaszmann; W T Everaerd; A A Haspels
Journal:  Am J Obstet Gynecol       Date:  1993-03       Impact factor: 8.661

Review 6.  Migraine in perimenopausal women.

Authors:  G Allais; G Chiarle; F Bergandi; C Benedetto
Journal:  Neurol Sci       Date:  2015-05       Impact factor: 3.307

7.  Symptoms in the menopausal transition: hormone and behavioral correlates.

Authors:  Ellen W Freeman; Mary D Sammel; Hui Lin; Clarisa R Gracia; Shiv Kapoor
Journal:  Obstet Gynecol       Date:  2008-01       Impact factor: 7.661

8.  Migraine prevalence during menopausal transition.

Authors:  Shuu-Jiun Wang; Jong-Ling Fuh; Shiang-Ru Lu; Kai-Dih Juang; Peng-Hui Wang
Journal:  Headache       Date:  2003-05       Impact factor: 5.887

9.  Characteristics of headache at menopause: a clinico-epidemiologic study.

Authors:  I Neri; F Granella; R Nappi; G C Manzoni; F Facchinetti; A R Genazzani
Journal:  Maturitas       Date:  1993-07       Impact factor: 4.342

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.